DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

Size: px
Start display at page:

Download "DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA."

Transcription

1 Viral Load

2 DNA >> Standard

3 PCR standard 0 Copies Catalog Number: 1122 Lot Number: Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Description: 10 reactions of a negative control template for use alongside HIV-1 Z6 DNA PCR standards (Cat#'s ). -80 o C. Contributor: Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems. Produced by the VQA Laboratory at Rush University Medical Center. References: Hart C, Chant S-Y, Kwok S, Sninsky J, Ou C-Y, Schochetman G. A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Research 18: , Abstract Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID, NIH: PCR Standard 0 copies (cat# 1122) from Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 1

4 PCR Standards 1 Copy Catalog Number: 4676 Lot Number: Release Category: A Provided: 500 µl of HIV-1 Z6 DNA at 1 copy/50 µl in 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Description: 10 reactions of HIV-1 Z6 DNA at 1 copy/50 µl. -80 o C. Contributor: Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems. Produced by the VQA Laboratory at Rush University Medical Center. References: Hart C, Chant S-Y, Kwok S, Sninsky J, Ou C-Y, Schochetman G. A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Research 18: , Abstract Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID, NIH: PCR Standards 1 Copy (cat# 4676) from Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 1

5 PCR Standards 20 Copies Catalog Number: 4677 Lot Number: Release Category: A Provided: 500 µl of HIV-1 Z6 DNA at 20 copies/50 µl in 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Description: 10 reactions of HIV-1 Z6 DNA at 20 copies/50 µl. -80 o C. Contributor: Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems. Produced by the VQA Laboratory at Rush University Medical Center. References: Hart C, Chant S-Y, Kwok S, Sninsky J, Ou C-Y, Schochetman G. A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Research 18: , Abstract Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID, NIH: PCR Standards 20 Copies (cat# 4677) from Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 1

6 PCR Standards 50 Copies Catalog Number: 4678 Lot Number: Release Category: A Provided: 500 µl of HIV-1 Z6 DNA at 50 copies/50 µl in 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Description: 10 reactions of HIV-1 Z6 DNA at 50 copies/50 µl. -80 o C. Contributor: Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems. Produced by the VQA Laboratory at Rush University Medical Center. References: Hart C, Chant S-Y, Kwok S, Sninsky J, Ou C-Y, Schochetman G. A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Research 18: , Abstract Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID, NIH: PCR Standards 50 Copies (cat# 4678) from Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 1

7 pvqa Catalog Number: Lot Number: Release Category: E Provided: 10µl at 10ng/µl in 10mM Tris. Description: A plasmid standard used for an HIV-1 mrna quantification assay. This assay utilizes a primer in the 3'LTR of HIV-1 and a poly-a anchored primer to specifically detect all poly-adenylated HIV-1 mrna species. The pvqa plasmid contains the last ~350 nucleotides of HIV-1 mrna as well as ~30 deoxyadenosine residues. Special Characteristics: This plasmid can be utilized as a DNA standard for qpcr reactions, or can be used as a template for in vitro transcription of an RNA standard for RT-qPCR. SEQUENCE -20 C Contributor: Dr. Robert Siliciano, Johns Hopkins School of Medicine References: Shan L, Rabi SA, Laird GM, Eisele EE, Zhang H, Margolick JB, Siliciano RF. A novel PCR assay for quantification of HIV-1 RNA. J Virol Jun;87(11): ABSTRACT Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat# pvqa from Dr. Robert Siliciano." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 2

8 REV: 12/10/2017 Page 2 of 2

9 PCR Standards 100 Copies Catalog Number: 4679 Lot Number: Release Category: A Provided: 500 µl of HIV-1 Z6 DNA at 100 copies/50 µl in 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Description: 10 reactions of HIV-1 Z6 DNA at 100 copies/50 µl. -80 C Contributor: Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems. Produced by the VQA Laboratory at Rush University Medical Center. References: Hart C, Chant S-Y, Kwok S, Sninsky J, Ou C-Y, Schochetman G. A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Research 18: , Abstract Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID, NIH: PCR Standards 100 Copies (cat# 4679) from Dr. Shirley Kwok and Dr. Cindy Christopherson, Roche Molecular Systems." Also include the reference cited above in any publications. REV: 12/10/2017 Page 1 of 1

10 HMA Kits >> Complete Kits

11 Heteroduplex Mobility Analysis HIV-1 gag Subtyping Kit Catalog Number: 5210 Lot Number: 9 Release Category: D Provided: The HMA Gag Kit includes primers, control plasmid DNA, and reference strains. Click here to view kit contents -70 C. Upon receipt, place the Primers and the Plasmids in separate boxes to avoid DNA cross contamination. Contributor: Drs. Leo Heyndrickx, Gert Van der Auwera, and Guido van der Groen. References: Website references: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HMA HIV-1 Gag Subtyping Kit from Drs. Guido van der Groen, Leo Heyndrickx and Gert Van der Auwera." REV: 12/10/2017 Page 1 of 1

12 Heteroduplex Mobility Analysis HIV-1 env Subtyping Kit Catalog Number: 2751 Lot Number: Release Category: D Provided: The HMA Kit contains primers, control plasmid DNA, and reference strains. Click here to view kit contents -70 C. Upon receipt, place the Primers and the Plasmids in separate boxes to avoid DNA cross contamination. Contributor: Dr. James Mullins References: Website reference: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HMA HIV-1 Env Subtyping Kit from Dr. James Mullins." REV: 12/10/2017 Page 1 of 1

13 OLA Kits >> All

14 OLA Kit for the Detection of HIV-1 Resistance Mutations to NRTIs Catalog Number: 7645 Lot Number: Release Category: A Provided: Each kit contains plasmids, primers, codon-specific oligonucleotides and control genomic DNA. Click here to view kit contents Description: Used for the detection of resistance mutations to nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, tenofovir, zalcitabine, zidovudine). OLA Kit Manual v C Contributor: Dr. Ingrid Beck, Dr. Lisa Frenkel, and DAIDS, NIAID. Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: OLA Kit, NRTIs (Cat #7645) from Dr. Ingrid Beck and Dr. Lisa Frenkel. REV: 12/10/2017 Page 1 of 1

15 OLA KIT for the Detection of HIV-1 Resistance Mutations to NNRTIs Catalog Number: 7644 Lot Number: Release Category: A Provided: Each kit contains plasmids, primers, codon-specific oligonucleotides and control genomic DNA. Click here to view kit contents Description: Used for the detection of HIV-1 resistance mutations to non-nucleoside reverse transcriptase inhibitors (nevirapine, delavirdine, efavirenz) OLA Kit Manual v C Contributor: Dr. Ingrid Beck, Dr. Lisa Frenkel, and DAIDS, NIAID. Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: OLA Kit, NNRTIs (Cat #7644) from Drs. Ingrid Beck and Lisa Frenkel. REV: 12/10/2017 Page 1 of 1

16 OLA Kit for the Detection of HIV-1 Resistance Mutations to Protease Inhibitors Catalog Number: 7643 Lot Number: 3 Release Category: A Provided: Each kit contains plasmid DNAs, primers, codon-specific oligonucleotides and control genomic DNA. Click here to view kit contents Description: Used for the detection of HIV-1 resistance mutations to protease inhibitors (nelfinavir, saquinavir, indinavir, ritonavir, and amprenavir). OLA Kit Manual v C Contributor: Drs. Ingrid Beck and Lisa Frenkel, and DAIDS, NIAID. Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: OLA Kit, Protease Inhibitors (Cat #7643), from Drs. Ingrid Beck and Lisa Frenkel. REV: 12/10/2017 Page 1 of 1

17 RNA >> Standard

18 AMΔHIV Catalog Number: 1913 Lot Number: 1 03/93 Release Category: A Provided: 1 ml cell-free virus Description: A 267 bp synthetic HIV-1MN gag sequence designed by Dr. Gregory Milman, DAIDS, NIAID, was cloned into the SalI-HindIII site of the retroviral vector pln6 by Drs. Janice Clements and Paula Pitha-Rowe (The Johns Hopkins University). Original Source: A 267 bp gag fragment (sequence supplied by Dr. Gregory Milman, DAIDS) was cloned into the synthetic HIV-1 MN SalI-HindIII sites of the retroviral vector plnl6. The viral particles were collected from infected PA317 cells transfected with the recombinant vector. Host: PA317 packaging cells. Titer: 2.0 x 10 7 copies/ml (Roche) 1.4 x 10 7 copies/ml (NASBA) Special Characteristics: This virus serves as an internal standard for detection of HIV RNA by RT-PCR. The gag fragment contains small deletions to distinguish it from wild type HIV-1 (see attached). SK38/SK39 or SK145/SK101 primers can be used for RT PCR. The amplified product can be distinguished from full-length HIV-1 gag RNA by liquid hybridizaion followed by gel electorphoresis. 1 µl of the virus is sufficient for PCR analysis and quantitation. Gag sequence Sterility: Negative for bacteria and mycoplasma. REV: 12/10/2017 Page 1 of 2

19 Liquid nitrogen. Contributor: Division of AIDS, NIAID, NIH, and Dr. Paula Pitha-Rowe. References: Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6: , Bender MA, Palmer TD, Gelinas RE, Miller AD. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol 61: , Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID: AMΔHIV from Dr. Paula Pitha-Rowe." Also include the references cited above in any publications. REV: 12/10/2017 Page 2 of 2

20 HIV-1 VQA RNA Quantification Standard Catalog Number: 3443 Lot Number: Release Category: D Provided: 1.25 ml, 150,000 copies HIV-1 RNA/mL spiked into HIV negative human serum to obtain final concentration. Contains EDTA. Description: Quantified live infectious virus spiked into HIV negative human serum. Original Source: HIV-1 qualitative cultures from known positive donors. Special Characteristics: This virus concentrate can be used to quantify HIV-1 RNA for viral detection assays. Virus stock used for this standard is a pool of B subtype HIV cultured from the PBMCs of 5 separate HIV-infected donors who were naïve to antiretroviral treatment. The virus culture supernatants were clarified of all cellular material and pooled. The virus stock was diluted in a commercial pooled true normal serum that is also clarified by filtration and EDTA is added at a final concentration of 6mM to mirror negative human EDTA plasma. Liquid nitrogen. Contributor: DAIDS Virology Quality Assurance (VQA) Program, Rush Presbyterian-St. Luke s Medical Center, Chicago, IL. Director: Dr. James Bremer. References: Yen-Lieberman B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 34: , Abstract REV: 12/10/2017 Page 1 of 2

21 Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, DAIDS, NIAID: HIV-1 VQA RNA Quantification Standard from the DAIDS Virology Quality Assurance (VQA) Program." Also include the reference cited above in any publications. REV: 12/10/2017 Page 2 of 2

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

Management of NRTI Resistance

Management of NRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington

More information

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920 0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal

More information

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness CLINICAL MICROBIOLOGY REVIEWS, Oct. 2007, p. 550 578 Vol. 20, No. 4 0893-8512/07/$08.00 0 doi:10.1128/cmr.00017-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Clinical Significance

More information

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets. Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,

More information

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is

More information

MedChem 401~ Retroviridae. Retroviridae

MedChem 401~ Retroviridae. Retroviridae MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The

More information

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed

More information

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f. Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

VQA Control SOP Version 4.0 Roche Amplicor HIV-1 DNA Test, v August 2007

VQA Control SOP Version 4.0 Roche Amplicor HIV-1 DNA Test, v August 2007 1. PRINCIPLE 1.1. The Virology Quality Assurance (VQA) Laboratory provides external cell pellet controls for use in the validation of assays that detect HIV proviral DNA. 1.2. HIV seronegative peripheral

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

Recombinant Protein Expression Retroviral system

Recombinant Protein Expression Retroviral system Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential

More information

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded

More information

Milan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002

Milan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002 Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay

More information

Certificate of Analysis

Certificate of Analysis Certificate of Analysis plvx-ef1α-ires-puro Vector Table of Contents Product Information... 1 Description... 2 Location of Features... 3 Additional Information... 3 Quality Control Data... 4 Catalog No.

More information

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:

More information

Introduction: Table/Figure Descriptions:

Introduction: Table/Figure Descriptions: Introduction: We have completed the analysis of your HIV RNA Validation Study. The validation plan was designed to verify the installation of an unmodified FDA-approved HIV RNA assay into your laboratory.

More information

Antiviral Chemotherapy

Antiviral Chemotherapy Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus

More information

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)

More information

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department

More information

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

More information

HIV and AIDS. Shan Nanji

HIV and AIDS. Shan Nanji HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein

More information

DIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:

DIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA: Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):

More information

Human Immunodeficiency Virus-1 (HIV-1) Genemer. Primer Pair for amplification of HIV-1 Specific DNA Fragment

Human Immunodeficiency Virus-1 (HIV-1) Genemer. Primer Pair for amplification of HIV-1 Specific DNA Fragment Product Manual Human Immunodeficiency Virus-1 (HIV-1) Genemer Primer Pair for amplification of HIV-1 Specific DNA Fragment Catalog No.: 60-2002-10 Store at 20 o C For research use only. Not for use in

More information

HIV medications HIV medication and schedule plan

HIV medications HIV medication and schedule plan Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with

More information

Anumber of clinical trials have demonstrated

Anumber of clinical trials have demonstrated IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines

More information

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine

More information

VQA HIV DNA Control SOP Version 5.0 HIV DNA Testing 13 March 2012

VQA HIV DNA Control SOP Version 5.0 HIV DNA Testing 13 March 2012 1. PRINCIPLE 1.1. The Virology Quality Assurance (VQA) Laboratory provides external cell pellet controls for use in the validation of assays that detect HIV proviral DNA. 1.2. HIV seronegative peripheral

More information

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Certificate of Analysis

Certificate of Analysis Certificate of Analysis Catalog No. Amount Lot Number 631987 10 μg Specified on product label. Product Information plvx-ef1α-ires-mcherry is a bicistronic lentiviral expression vector that can be used

More information

HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis

HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis Product Manual HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis For research use only. Not for use in diagnostic procedures for clinical purposes Catalog

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of

More information

Industry Data Request

Industry Data Request Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,

More information

Hepatitis B Virus Genemer

Hepatitis B Virus Genemer Product Manual Hepatitis B Virus Genemer Primer Pair for amplification of HBV Viral Specific Fragment Catalog No.: 60-2007-10 Store at 20 o C For research use only. Not for use in diagnostic procedures

More information

ORIGINAL ARTICLE /j x. Brescia, Italy

ORIGINAL ARTICLE /j x. Brescia, Italy ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive

More information

Sequences in the 5 and 3 R Elements of Human Immunodeficiency Virus Type 1 Critical for Efficient Reverse Transcription

Sequences in the 5 and 3 R Elements of Human Immunodeficiency Virus Type 1 Critical for Efficient Reverse Transcription JOURNAL OF VIROLOGY, Sept. 2000, p. 8324 8334 Vol. 74, No. 18 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Sequences in the 5 and 3 R Elements of Human

More information

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics

More information

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors Journal of Clinical Virology 13 (1999) 71 80 Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors Hauke Walter a, Barbara Schmidt a, Klaus Korn a, Anne-Mieke

More information

HIV - Life cycle. HIV Life Cyle

HIV - Life cycle. HIV Life Cyle Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic

More information

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

HIV associated CNS disease in the era of HAART

HIV associated CNS disease in the era of HAART HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious

More information

Antiviral Drugs Lecture 5

Antiviral Drugs Lecture 5 Antiviral Drugs Lecture 5 Antimicrobial Chemotherapy (MLAB 366) 1 Dr. Mohamed A. El-Sakhawy 2 Introduction Viruses are microscopic organisms that can infect all living cells. They are parasitic and multiply

More information

AIDS - Knowledge and Dogma. Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/ , Vienna, Austria

AIDS - Knowledge and Dogma. Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/ , Vienna, Austria AIDS - Knowledge and Dogma Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/17 2010, Vienna, Austria Reliability of PCR to detect genetic sequences from HIV Juan Manuel

More information

Panther has new prey

Panther has new prey Raising the Bar for Performance Testing Panther has new prey The Aptima HIV-1 Quant Dx assay leads the hunt for HIV-1 diagnosis and viral load monitoring. Freedom to work the way you choose Run what assays

More information

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014 Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss

More information

Because accurate and reproducible phenotypic susceptibility

Because accurate and reproducible phenotypic susceptibility BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and

More information

Industry Request Integrase Inhibitors

Industry Request Integrase Inhibitors Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical

More information

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase. Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.

More information

Antiviral Therapy 2011; 16: (doi: /IMP1851)

Antiviral Therapy 2011; 16: (doi: /IMP1851) Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure

More information

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University

More information

HIV-1 Viral Load Real Time (RG)

HIV-1 Viral Load Real Time (RG) -1 Viral Load Real Time (RG) Real Time RT-PCR type 1 RNA quantification assay MSP Reg. pending Valdense 3616. 11700. Montevideo. Uruguay. phone (598) 2 336 83 01. Fax (598) 2 336 71 60. Info@atgen.com.uy

More information

Nobel /03/28. HIV virus and infected CD4+ T cells

Nobel /03/28. HIV virus and infected CD4+ T cells Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Retro-X qrt-pcr Titration Kit User Manual

Retro-X qrt-pcr Titration Kit User Manual Takara Bio USA Retro-X qrt-pcr Titration Kit User Manual Cat. No. 631453 PT3952-1 (030218) 1290 Terra Bella Avenue, Mountain View, CA 94043, USA U.S. Technical Support: techus@takarabio.com United States/Canada

More information

~Lentivirus production~

~Lentivirus production~ ~Lentivirus production~ May 30, 2008 RNAi core R&D group member Lentivirus Production Session Lentivirus!!! Is it health threatening to lab technician? What s so good about this RNAi library? How to produce

More information

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital. Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T

More information

Characteristics and outcomes of individuals enrolled for HIV care in a rural clinic in Coastal Kenya Hassan, A.S.

Characteristics and outcomes of individuals enrolled for HIV care in a rural clinic in Coastal Kenya Hassan, A.S. UvA-DARE (Digital Academic Repository) Characteristics and outcomes of individuals enrolled for HIV care in a rural clinic in Coastal Kenya Hassan, A.S. Link to publication Citation for published version

More information

Received 4 August 2005/Accepted 7 December 2005

Received 4 August 2005/Accepted 7 December 2005 JOURNAL OF VIROLOGY, Mar. 2006, p. 2472 2482 Vol. 80, No. 5 0022-538X/06/$08.00 0 doi:10.1128/jvi.80.5.2472 2482.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Extensive Recombination

More information

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

HIV/AIDS CID 2003:37 (1 July) 113

HIV/AIDS CID 2003:37 (1 July) 113 MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,

More information

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.

More information

Technical Bulletin No. 162

Technical Bulletin No. 162 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

C h a p t e r 5 5 HIV Therapy Where are We Now?

C h a p t e r 5 5 HIV Therapy Where are We Now? C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type

More information

Evaluation and Management of Virologic Failure

Evaluation and Management of Virologic Failure National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:

More information

7.014 Problem Set 7 Solutions

7.014 Problem Set 7 Solutions MIT Department of Biology 7.014 Introductory Biology, Spring 2005 7.014 Problem Set 7 Solutions Question 1 Part A Antigen binding site Antigen binding site Variable region Light chain Light chain Variable

More information

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves

More information

Received 21 April 2005/Accepted 21 June 2005

Received 21 April 2005/Accepted 21 June 2005 JOURNAL OF VIROLOGY, Sept. 2005, p. 12045 12057 Vol. 79, No. 18 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.18.12045 12057.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Human

More information

HIV epidemiology since HIV in the United States. HIV Transmission

HIV epidemiology since HIV in the United States. HIV Transmission HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United

More information

Margaret A. Daugherty. Announcements! Fall Michaelis Menton Kinetics and Inhibition. Lecture 14: Enzymes & Kinetics III

Margaret A. Daugherty. Announcements! Fall Michaelis Menton Kinetics and Inhibition. Lecture 14: Enzymes & Kinetics III Lecture 14: Enzymes & Kinetics III Michaelis Menton Kinetics and Inhibition Margaret A. Daugherty Fall 2004 Announcements! Monday 10/11 lecture: starts at 10:15; Taught by Dr. Stephen Everse o ffice our/review

More information

Reverse transcription and integration

Reverse transcription and integration Reverse transcription and integration Lecture 9 Biology 3310/4310 Virology Spring 2018 One can t believe impossible things, said Alice. I dare say you haven t had much practice, said the Queen. Why, sometimes

More information

HIV-1 Dual Infection and Neurocognitive Impairment

HIV-1 Dual Infection and Neurocognitive Impairment HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral

More information

Central Nervous System Penetration of ARVs: Does it Matter?

Central Nervous System Penetration of ARVs: Does it Matter? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15

More information

Packaging and Abnormal Particle Morphology

Packaging and Abnormal Particle Morphology JOURNAL OF VIROLOGY, OCt. 1990, p. 5230-5234 0022-538X/90/105230-05$02.00/0 Copyright 1990, American Society for Microbiology Vol. 64, No. 10 A Mutant of Human Immunodeficiency Virus with Reduced RNA Packaging

More information

Molecular Diagnosis Future Directions

Molecular Diagnosis Future Directions Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular

More information

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent

More information

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication DEFINITIONS OF TERMS Eukaryotic: Non-bacterial cell type (bacteria are prokaryotes).. LESSON 4.4 WORKBOOK How viruses make us sick: Viral Replication This lesson extends the principles we learned in Unit

More information

Clinical Management of HIV Drug Resistance

Clinical Management of HIV Drug Resistance Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *

More information

Fig. 1: Schematic diagram of basic structure of HIV

Fig. 1: Schematic diagram of basic structure of HIV UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?

More information

Technical Bulletin No. 161

Technical Bulletin No. 161 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE: FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Norgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler

Norgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler 3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product # 33840 Product Insert Background Information

More information

Norgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler

Norgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler 3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product# 33840 Product Insert Intended

More information

Chapter 49. Antiviral Agents

Chapter 49. Antiviral Agents Chapter 49 Antiviral Agents Antiviral Drugs 1. Characters of Virus Viruses are obligate intracellular parasites their replication depends primarily on synthetic processes of the host cell. 2.Classification

More information

Viruses. Picture from:

Viruses. Picture from: Viruses Understand the structure of bacteriophages & human immunodeficiency virus (HIV) Appreciate that viruses replicate in host cells (thereby destroying them) Picture from: http://eands.caltech.edu/articles/lxvii1/viruses.html

More information

HIV & AIDS: Overview

HIV & AIDS: Overview HIV & AIDS: Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR VJ TEMPLE 1 What

More information

Introduction retroposon

Introduction retroposon 17.1 - Introduction A retrovirus is an RNA virus able to convert its sequence into DNA by reverse transcription A retroposon (retrotransposon) is a transposon that mobilizes via an RNA form; the DNA element

More information